Ann: MGC Pharma COVID-19 Business and Operations Update, page-74

Following on with the theme of no long term agreement in place for the use of Graft Polymer's SNEDDS technology and no royalties agreement or similar in place.

MXC have today announced they have filed a patent application for CimetrA using "Graft Polymers proprietary" SNEDDS delivery technology.

I would say that is great news for Graft Polymer, Roby, Brett and Eastman but is it grwat for MXC? As Graft Polymer now have a company patenting a drug with their technology and wanting to use it in the future without any agreement for long term use in place basically meaning they can name their price in any negotiations, as without it, MXC can't use the patent or CimetrA. MXC will need to pay the price demanded for long term use of the technology or they will need to start again with developement of CimetrA But they already paid over $500k in R&D to have that developed

The delivery system is the only novel thing that may be able to be patented.... Who wins from this deal? Wouldn't be Graft Polymer and by extension Brett, Roby and Eastman would it? No, surely not

Just another corporate heist underway.......

All good guys, BUY THE DIP lol